Annual report
2413.TEDINET S100YJ25
Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥351.4bn | 2025-04-01 → 2026-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥284.9bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥238.9bn | 2023-04-01 → 2024-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥230.8bn | 2022-04-01 → 2023-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥208.2bn | 2021-04-01 → 2022-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥73.5bn | 2025-04-01 → 2026-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥63.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥76.3bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥64.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥68.8bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥74.3bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥96.2bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥49.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥40.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥45.3bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥49.0bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥63.8bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥54.0bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥44.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥637.4bn | at 2026-03-31 | Cons. | Assets IFRS |
| Total assets | ¥581.7bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥490.8bn | at 2024-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥400.6bn | at 2023-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥346.0bn | at 2022-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥190.7bn | at 2026-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥168.9bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥446.6bn | at 2026-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥412.8bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥366.7bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥408.2bn | at 2026-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥378.4bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥351.9bn | at 2024-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥302.6bn | at 2023-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥257.8bn | at 2022-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥156.2bn | at 2026-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥134.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥149.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥118.3bn | at 2023-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥104.3bn | at 2022-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥70.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥51.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥58.3bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥57.1bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥52.1bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥15.9bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥39.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥39.5bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥21.9bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥23.4bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥35.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥27.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥9.4bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥16.4bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥72.53 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥59.62 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥66.68 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥72.22 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥94.06 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥72.5 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥59.6 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥66.63 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥72.17 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥93.98 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥608.98 | at 2026-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥555.07 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥516.49 | at 2024-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥444.22 | at 2023-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥378.75 | at 2022-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 64.0% | at 2026-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.1% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.7% | at 2024-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 75.5% | at 2023-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.5% | at 2022-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 12.5% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.8% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 17.5% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 27.9% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 17,010 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 15,360 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 12,100 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 10,533 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 9,384 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥47.2bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥45.2bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥51.5bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥54.5bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥55.7bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥21.0bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥19.1bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥28.3bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥27.5bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥84.0bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥28.0bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥32.3bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥31.9bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥27.4bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥24.0bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥21.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥75.9bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥19.8bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥20.5bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥268.7bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥265.1bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥251.2bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥232.6bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥215.4bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥45.4bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥31.9bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥223.3bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥233.1bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥226.0bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥162.1bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥152.5bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥79.8bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥78.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥35.44 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.56 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥111.85 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.14 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.17 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥35.43 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥31.56 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥111.77 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥29.12 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥30.15 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥22 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥21 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥21 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥19 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥332.42 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥341.34 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥331.17 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥237.22 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥223.54 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 82.6% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.4% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.2% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.4% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 10.6% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 39.4% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.6% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 679,120,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 679,077,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 679,063,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,964,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,904,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 750 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 704 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 649 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 588 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 574 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 68
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥4.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥4.2bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥1.6bn |
| Career Solutionreportable segment | employees | at 2026-03-31 | 1061 pure |
| Career Solutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥22.8bn |
| Career Solutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥22.7bn |
| Career Solutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥75m |
| Career Solutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥5.9bn |
| Evidence Solutionreportable segment | employees | at 2026-03-31 | 2361 pure |
| Evidence Solutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥24.5bn |
| Evidence Solutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥24.4bn |
| Evidence Solutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥167m |
| Evidence Solutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥5.1bn |
| Medical Platformreportable segment | employees | at 2026-03-31 | 3407 pure |
| Medical Platformreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥107.8bn |
| Medical Platformreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥104.0bn |
| Medical Platformreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥3.8bn |
| Medical Platformreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥35.9bn |
| Overseasreportable segment | employees | at 2026-03-31 | 3065 pure |
| Overseasreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥86.9bn |
| Overseasreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥86.9bn |
| Overseasreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥16m |
| Overseasreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥14.9bn |
| Patient Solutionreportable segment | employees | at 2026-03-31 | 1208 pure |
| Patient Solutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥56.9bn |
| Patient Solutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥56.9bn |
| Patient Solutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥4m |
| Patient Solutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥2.7bn |
| Site Solutionreportable segment | employees | at 2026-03-31 | 5740 pure |
| Site Solutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥54.4bn |
| Site Solutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥54.3bn |
| Site Solutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥7m |
| Site Solutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥5.8bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥353.3bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥349.2bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥4.1bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥70.3bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥3.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥3.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥3.1bn |
| Career Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥20.9bn |
| Career Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥20.9bn |
| Career Solutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥32m |
| Career Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.7bn |
| Evidence Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥24.2bn |
| Evidence Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥24.0bn |
| Evidence Solutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥223m |
| Evidence Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.3bn |
| Medical Platformreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥91.6bn |
| Medical Platformreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥88.2bn |
| Medical Platformreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.4bn |
| Medical Platformreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥34.1bn |
| Overseasreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥80.6bn |
| Overseasreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥80.5bn |
| Overseasreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥64m |
| Overseasreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥14.7bn |
| Patient Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥21.9bn |
| Patient Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥21.9bn |
| Patient Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥824m |
| Site Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥47.0bn |
| Site Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥47.0bn |
| Site Solutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥12m |
| Site Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.4bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥286.3bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥282.5bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥65.1bn |
| Medical Platformreportable segment | employees | at 2026-03-31 | 658 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,852
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 704 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 750 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 291 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 278 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 271 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 211 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 188 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.592 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.441 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.290 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.235 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.225 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.020 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.079 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.525 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.502 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.022 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 40 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 38 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 61 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 79 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 40 | |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 12859000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05425-000MedicalPlatformReportableSegmentMember | 3043000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05425-000EvidenceSolutionReportableSegmentMember | 214000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05425-000CareerSolutionReportableSegmentMember | 219000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05425-000SiteSolutionReportableSegmentMember | 6690000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05425-000PatientSolutionReportableSegmentMember | 346000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05425-000OverseasReportableSegmentMember | 2307000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 679120300 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 679124300 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 679120300 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 679124300 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 31 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 57 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 746 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 692 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 249 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 70070 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 71845 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 1574435 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 77901 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 2365559 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 2015210 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 2120 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 753861 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 6789086 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |